Reata Pharmaceuticals Inc. (RETA): Detailed Summary on Healthcare Stock

0
102

Reata Pharmaceuticals Inc. (NASDAQ:RETA) changes shares on Friday trading session, with a change of 10.04% or $16.11 shares. The trading starts at $161.62 and closed at $160.45 throughout the day. The trading session low price was $158.79 and day high was $178.43 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.63 million while its average volume is 337.34K. In other hand, the RETA market cap reached to $6.03B. While, its current target price is $176.56 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 8.15% and up 12.27% for month. Its quarterly performance was 42.20% above, while its half year performance is down -17.14%. RETA yearly performance stood at positive 104.97% and fall -13.63% for year-to-date. Current recommendation for Reata Pharmaceuticals Inc. is 1.40.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. RETA EPS (TTM) for 12-month is -9.84. EPS for this year is -228.10%, while for the next year its value is -10.18. Its EPS Q/Q reached -50.70%.

Let’s take a look on the analyst recommendations on RETA for the current month and previous month. For the current month, 7 of 8 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 7 analysts participate in stock recommendation. Out of 7, 0 rated it sell, 6 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $237.00-$345.00. Average target price for RETA was reached at $285.50.

CPMG INC, Wellington Management Company, LLP and Vanguard Group, Inc. (The) are the top three holders in Reata Pharmaceuticals Inc. (RETA) stock. On Mar 30, 2020, CPMG INC has 3.06 million shares which valued 442.2 million. On Mar 30, 2020, Wellington Management Company, LLP owned 3.02 million shares which valued at 436.04 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 2.24 million shares which valued at 323.28 million. In the end, Vanguard Group, Inc. (The) have 7.95% shares outstanding of Reata Pharmaceuticals Inc. (RETA) on Mar 30, 2020. The insider ownership moved to 0.70% and institutional holding shifted to 81.20%.

The company posted an EPS (TTM) of -9.84. According to the most recent quarter report on (Jun 2020), 8 analysts estimated an average EPS of -2.76, while -1.14 EPS posted a year ago period. Analyst Estimated EPS for RETA published in the report was -6.44–1.98 during the same period. Comparing with last year, the average estimated EPS was -1.14 which is higher than -1.47 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for RETA rise 5.19% for period of 200 days. SMA for 50 days was 16.46% which is showing green signal, while SMA-20 was 18.91%. The moving average value for Reata Pharmaceuticals Inc. (RETA) is 177.86 and 152.47 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in RETA stock. On Jun 01, Castellanos Elaine, VP, Chief Accounting Officer, sold 2,000 trading shares at the cost of $143.97, which valued at 0.29 million. On Mar 02, Castellanos Elaine, VP, Chief Accounting Officer, sold 2,000 shares at the cost of $194.32, with total shares of 15,146. On Dec 16, Wilson Jason Douglas, Executive VP of Operations, sold 10,000 shares at the cost of 203.26. After this transaction, Wilson Jason Douglas total shares reached to 12,950 which valued at 2.03 million.